JP2015529210A - 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用 - Google Patents

眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用 Download PDF

Info

Publication number
JP2015529210A
JP2015529210A JP2015530372A JP2015530372A JP2015529210A JP 2015529210 A JP2015529210 A JP 2015529210A JP 2015530372 A JP2015530372 A JP 2015530372A JP 2015530372 A JP2015530372 A JP 2015530372A JP 2015529210 A JP2015529210 A JP 2015529210A
Authority
JP
Japan
Prior art keywords
sirna
eye
seq
administered
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015530372A
Other languages
English (en)
Japanese (ja)
Inventor
イサベル ヒメネス アントン アナ
イサベル ヒメネス アントン アナ
ゴンザレス ファハルド ヴィクトリア
ゴンザレス ファハルド ヴィクトリア
ルース パロマ ヴェロニカ
ルース パロマ ヴェロニカ
Original Assignee
シレンティス・エセ・ア・ウ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シレンティス・エセ・ア・ウ filed Critical シレンティス・エセ・ア・ウ
Publication of JP2015529210A publication Critical patent/JP2015529210A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015530372A 2012-09-05 2013-09-04 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用 Pending JP2015529210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1215857.2 2012-09-05
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/EP2013/068245 WO2014037377A1 (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090693A Division JP6742362B2 (ja) 2012-09-05 2018-05-09 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用

Publications (1)

Publication Number Publication Date
JP2015529210A true JP2015529210A (ja) 2015-10-05

Family

ID=47136985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015530372A Pending JP2015529210A (ja) 2012-09-05 2013-09-04 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用
JP2018090693A Active JP6742362B2 (ja) 2012-09-05 2018-05-09 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018090693A Active JP6742362B2 (ja) 2012-09-05 2018-05-09 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用

Country Status (29)

Country Link
US (1) US9808479B2 (enExample)
EP (1) EP2893019B1 (enExample)
JP (2) JP2015529210A (enExample)
KR (1) KR102136539B1 (enExample)
CN (2) CN104640988A (enExample)
AU (1) AU2013311781B2 (enExample)
BR (1) BR112015004469B8 (enExample)
CA (1) CA2883040C (enExample)
CL (1) CL2015000537A1 (enExample)
CY (1) CY1121000T1 (enExample)
DK (1) DK2893019T3 (enExample)
EC (1) ECSP15009391A (enExample)
ES (1) ES2685346T3 (enExample)
GB (1) GB201215857D0 (enExample)
HR (1) HRP20181079T1 (enExample)
HU (1) HUE040096T2 (enExample)
IL (1) IL237389B (enExample)
IN (1) IN2015DN02501A (enExample)
LT (1) LT2893019T (enExample)
MX (1) MX362854B (enExample)
PE (1) PE20150619A1 (enExample)
PL (1) PL2893019T3 (enExample)
PT (1) PT2893019T (enExample)
RS (1) RS57620B1 (enExample)
RU (1) RU2663100C2 (enExample)
SG (1) SG11201501386TA (enExample)
SI (1) SI2893019T1 (enExample)
WO (1) WO2014037377A1 (enExample)
ZA (1) ZA201501494B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6165723B2 (ja) 2011-06-30 2017-07-19 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
EP3923909A1 (en) 2019-02-15 2021-12-22 Novartis AG Methods for treating ocular surface pain
WO2021066144A1 (ja) * 2019-10-04 2021-04-08 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有医薬

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148193A1 (en) * 2010-05-27 2011-12-01 Sylentis S.A. Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP5578388B2 (ja) 2002-04-18 2014-08-27 オプコ ファーマシューティカルズ、エルエルシー 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
US20040146858A1 (en) 2002-07-24 2004-07-29 Immusol, Inc. Novel siRNA gene libraries and methods for their production and use
WO2004009796A2 (en) 2002-07-24 2004-01-29 Immusol Incorporated Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
EP1556402B1 (en) 2002-09-25 2011-06-22 University of Massachusetts In vivo gene silencing by chemically modified and stable sirna
EP1562970A4 (en) 2002-11-01 2006-04-12 Univ Pennsylvania COMPOSITIONS AND METHODS FOR SIRNAIL INHIBITION OF HIF-1 ALPHA
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
US20060241072A1 (en) 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
WO2005032493A2 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
JP5838017B2 (ja) * 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2005213484A1 (en) 2004-02-05 2005-08-25 Intradigm Corporation RNAi therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
HUE033977T2 (en) 2004-08-23 2018-02-28 Sylentis Sau Treatment of eye disorders with siRNAs characterized by increased intraocular pressure
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
JP2008533050A (ja) 2005-03-11 2008-08-21 アルコン，インコーポレイテッド 緑内障を処置するためのフリッツルド関連蛋白質―１のｒｎａｉ媒介性阻害
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
ZA200900553B (en) * 2006-08-24 2010-04-28 Alcon Res Ltd Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions
WO2009023025A1 (en) 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN201337650Y (zh) * 2009-01-06 2009-11-04 河北科技大学 一次性药用单剂量液体容器

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148193A1 (en) * 2010-05-27 2011-12-01 Sylentis S.A. Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Also Published As

Publication number Publication date
MX2015002802A (es) 2015-05-15
HK1212377A1 (en) 2016-06-10
EP2893019B1 (en) 2018-05-30
PE20150619A1 (es) 2015-05-11
RU2015112121A (ru) 2016-10-27
GB201215857D0 (en) 2012-10-24
KR102136539B1 (ko) 2020-07-23
IL237389A0 (en) 2015-04-30
LT2893019T (lt) 2018-08-10
AU2013311781B2 (en) 2018-10-18
KR20150047513A (ko) 2015-05-04
US20150224131A1 (en) 2015-08-13
EP2893019A1 (en) 2015-07-15
CL2015000537A1 (es) 2015-07-10
ZA201501494B (en) 2016-01-27
SG11201501386TA (en) 2015-03-30
US9808479B2 (en) 2017-11-07
DK2893019T3 (en) 2018-09-03
BR112015004469A2 (pt) 2017-08-08
ES2685346T3 (es) 2018-10-08
IL237389B (en) 2019-01-31
AU2013311781A1 (en) 2015-03-12
JP6742362B2 (ja) 2020-08-19
BR112015004469B1 (pt) 2022-11-16
PL2893019T3 (pl) 2018-12-31
PT2893019T (pt) 2018-10-19
CA2883040A1 (en) 2014-03-13
RS57620B1 (sr) 2018-11-30
BR112015004469B8 (pt) 2022-12-06
RU2663100C2 (ru) 2018-08-01
CN104640988A (zh) 2015-05-20
CY1121000T1 (el) 2019-12-11
IN2015DN02501A (enExample) 2015-09-11
WO2014037377A1 (en) 2014-03-13
ECSP15009391A (es) 2015-12-31
HRP20181079T1 (hr) 2018-09-07
CN108354944A (zh) 2018-08-03
SI2893019T1 (sl) 2018-09-28
HUE040096T2 (hu) 2019-02-28
MX362854B (es) 2019-02-20
CA2883040C (en) 2023-01-17
JP2018138596A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
JP6742362B2 (ja) 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用
AU2011256978B2 (en) siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP2013176395A (ja) 眼疾患の治療のための、１１β―ヒドロキシステロイド脱水素酵素の発現の調節
CN103097534A (zh) 针对rhoa的双链rna化合物及其用途
RU2653766C2 (ru) КиРНК И ИХ ИСПОЛЬЗОВАНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
PT1937281E (pt) Modulação dos níveis de expressão de trpv
JP2016535593A (ja) ＦＬＡＰ遺伝子の発現を阻害するための方法及び組成物におけるｓｉＲＮＡ及びその使用
HK1212377B (en) Sirna and its use in methods and compositions for the treatment and/or prevention of eye conditions
HK1183904A (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180509

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20180509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180518

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20180522

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180615

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20180619

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20181204

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190129

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20190212

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200616

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20200721

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20200721